Delivery Order SPE2DB25D3012-SPE2DB25FXAED
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,284.92 to AmerisourceBergen Drug Corp for COMBIPATCH 0.05-0.14 mg transdermal patches (8-count package) on September 24, 2025, with completion targeted for September 25, 2025. This non-set-aside contract was competitively awarded on a firm fixed price basis, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued...
- The Defense Logistics Agency awarded a delivery order valued at $2,779.42 to AmerisourceBergen Drug Corp for COMBIPATCH 0.05-0.25 MG transdermal patches (8-count) on September 24, 2025, with completion expected by September 25, 2025. This firm fixed-price, non-competitive delivery order was fulfilled without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency Medical Supply Chain awarded a $1,183.98 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for COMBIPATCH 0.05-0.14 mg transdermal patches (8-count package). This firm fixed-price delivery order, which was not subject to any set-aside designation, is scheduled for completion by June 3, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. COMBIPATCH is a combination hormone replacement therapy patch used to treat...
- This delivery order, valued at $1,463.46, was awarded to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Combipatch 0.05-0.14 mg transdermal patches (8-count) with a completion date of September 2, 2025. The contract utilizes firm fixed pricing with no set-aside designation, reflecting a competitively awarded transaction. AmerisourceBergen Drug Corp will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 5,231.17 in Combipatch transdermal patches (0.05-0.14 mg), with an ultimate completion date of August 15, 2025. This competitive award, issued on August 14, 2025, carries a firm fixed price structure and involves no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,050.80 firm fixed price delivery order to Amerisourcebergen Drug Corporation for COMBIPATCH 0.05-0.14 MG PTCH 8S. The order is to be performed by Amerisourcebergen's Conshohocken, Pennsylvania facility over the period of August 8-9, 2023. As the DLA is responsible for procuring medical supplies and pharmaceuticals for the U.S. military and other government agencies, this order is likely to deliver transdermal combination hormone replacement patches for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,094.93 to AmerisourceBergen Drug Corp for COMBIPATCH 0.05-0.14 MG patches (8-count) on August 8, 2025, with an ultimate completion date of August 11, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency (DLA) awarded a $3,430.71 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Combipatch 0.05-0.14 mg transdermal patches (8-count units). This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. Performance is scheduled for completion by September 3,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of Combipatch 0.05-0.14 mg patches (8-count package) with a ceiling value of $1,481.94. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by November 3, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $581,600 firm fixed price delivery order to Amerisourcebergen Drug Corporation for COMBIPATCH transdermal patches. Under this single day contract, Amerisourcebergen will supply 8,000 boxes of the 0.05-0.25 mg dosage patches to a Conshohocken, Pennsylvania facility from August 21-22, 2023. As a major provider of pharmaceuticals and medical supplies to the Department of Defense, this order for the combination estrogen and progestin patches supports the...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FXAEDDelivery Order
The Defense Logistics Agency awarded a $2,254.84 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of COMBIPATCH 0.05-0.14 MG transdermal patches (8-count packaging), with completion expected by September 18, 2025. This is a firm fixed-price contract with no set-aside designation, meaning it was competitively awarded. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor for federal medical procurement. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply medications and medical supplies to support military healthcare programs worldwide. COMBIPATCH, a combination hormone replacement therapy patch, represents the type of specialized pharmaceutical product that DLA procures through this vehicle to meet the ongoing medical supply needs of the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 9/17/25 |